EGFR and cancer: Molecular targeting using antibody technology in particular is well established in both preclinical and clinical settings, with many antibodies already approved by the FDA for cancer immunotherapy such as the anti-epidermal growth factor receptor (anti-EGFR) antibody [82, 83].